152 related articles for article (PubMed ID: 28869560)
1. Targeting PDE10A GAF Domain with Small Molecules: A Way for Allosteric Modulation with Anti-Inflammatory Effects.
García AM; Brea J; González-García A; Pérez C; Cadavid MI; Loza MI; Martinez A; Gil C
Molecules; 2017 Sep; 22(9):. PubMed ID: 28869560
[TBL] [Abstract][Full Text] [Related]
2. Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity.
Matthiesen K; Nielsen J
Biochem J; 2009 Oct; 423(3):401-9. PubMed ID: 19689430
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP.
Handa N; Mizohata E; Kishishita S; Toyama M; Morita S; Uchikubo-Kamo T; Akasaka R; Omori K; Kotera J; Terada T; Shirouzu M; Yokoyama S
J Biol Chem; 2008 Jul; 283(28):19657-64. PubMed ID: 18477562
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Design of Scaffolds Targeting PDE10A by INPHARMA-NMR.
Codutti L; Grimaldi M; Carlomagno T
J Chem Inf Model; 2017 Jun; 57(6):1488-1498. PubMed ID: 28569061
[TBL] [Abstract][Full Text] [Related]
5. Future directions in phosphodiesterase drug discovery.
DeNinno MP
Bioorg Med Chem Lett; 2012 Nov; 22(22):6794-800. PubMed ID: 23046962
[TBL] [Abstract][Full Text] [Related]
6. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11.
Gross-Langenhoff M; Hofbauer K; Weber J; Schultz A; Schultz JE
J Biol Chem; 2006 Feb; 281(5):2841-6. PubMed ID: 16330539
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor.
Kadoh Y; Miyoshi H; Matsumura T; Tanaka Y; Hongu M; Kimura M; Takedomi K; Omori K; Kotera J; Sasaki T; Kobayashi T; Taniguchi H; Watanabe Y; Kojima K; Sakamoto T; Himiyama T; Kawanishi E
Chem Pharm Bull (Tokyo); 2018; 66(3):243-250. PubMed ID: 29491258
[TBL] [Abstract][Full Text] [Related]
8. A substrate selectivity and inhibitor design lesson from the PDE10-cAMP crystal structure: a computational study.
Lau JK; Li XB; Cheng YK
J Phys Chem B; 2010 Apr; 114(15):5154-60. PubMed ID: 20349929
[TBL] [Abstract][Full Text] [Related]
9. Activation of PDE10 and PDE11 phosphodiesterases.
Jäger R; Russwurm C; Schwede F; Genieser HG; Koesling D; Russwurm M
J Biol Chem; 2012 Jan; 287(2):1210-9. PubMed ID: 22105073
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological tools based on imidazole scaffold proved the utility of PDE10A inhibitors for Parkinson's disease.
García AM; Salado IG; Perez DI; Brea J; Morales-García JA; González-García A; Cadavid MI; Loza MI; Luque FJ; Perez-Castillo A; Martinez A; Gil C
Future Med Chem; 2017 May; 9(8):731-748. PubMed ID: 28485668
[TBL] [Abstract][Full Text] [Related]
11. Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors.
Chino A; Seo R; Amano Y; Namatame I; Hamaguchi W; Honbou K; Mihara T; Yamazaki M; Tomishima M; Masuda N
Chem Pharm Bull (Tokyo); 2018; 66(3):286-294. PubMed ID: 29491261
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
[TBL] [Abstract][Full Text] [Related]
13. Functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains.
Hofbauer K; Schultz A; Schultz JE
J Biol Chem; 2008 Sep; 283(37):25164-25170. PubMed ID: 18635550
[TBL] [Abstract][Full Text] [Related]
14. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
Amin HS; Parikh PK; Ghate MD
Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
[TBL] [Abstract][Full Text] [Related]
15. The rational search for PDE10A inhibitors from Sophora flavescens roots using pharmacophore‑ and docking‑based virtual screening.
Fan HT; Guo JF; Zhang YX; Gu YX; Ning ZQ; Qiao YJ; Wang X
Mol Med Rep; 2018 Jan; 17(1):388-393. PubMed ID: 29115449
[TBL] [Abstract][Full Text] [Related]
16. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
[TBL] [Abstract][Full Text] [Related]
17. Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei.
Rascón A; Soderling SH; Schaefer JB; Beavo JA
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4714-9. PubMed ID: 11930017
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
[TBL] [Abstract][Full Text] [Related]
19. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
[TBL] [Abstract][Full Text] [Related]
20. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
